Cytosorbents (CTSO) Liabilities and Shareholders Equity (2010 - 2026)

Cytosorbents' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $40.6 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 20.12% year-over-year to $40.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.5 million (down 10.48% YoY) and the FY2025 annual result came in at $44.2 million, down 6.73% from the prior year.
• Liabilities and Shareholders Equity was $40.6 million for Q1 2026 at Cytosorbents, down from $44.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $83.3 million in Q1 2022 and bottomed at $40.6 million in Q1 2026.
• A 5-year average of $53.8 million and a median of $50.8 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 34.5% — and 2025, when it grew 7.88%.
• Cytosorbents' Liabilities and Shareholders Equity stood at $63.2 million in 2022, then declined by 16.25% to $53.0 million in 2023, then fell by 10.55% to $47.4 million in 2024, then decreased by 6.73% to $44.2 million in 2025, then dropped by 8.19% to $40.6 million in 2026.
• Business Quant data shows CTSO's Liabilities and Shareholders Equity at $40.6 million in Q1 2026, $44.2 million in Q4 2025, and $45.8 million in Q3 2025.